Sorted By:


ICYMI: New Commonwealth Fund Study Shows Health Insurance Does Not Always Translate to Affordable Care

PhRMA  |  Blog Post

Get ABC and other updates here.

Key Facts Card

PhRMA  |  Fact Sheet

Relentless scientific inquiry in drug development is shifting the odds in the fight against some of the world’s most challenging diseases. Industry facts from research and development to value of medicines to economic impact are outlined in the Fact Sheet below....

A new era in genomics

PhRMA  |  Blog Post

To learn more about the positive impact of the work being done by America’s biopharmaceutical companies, visit

YMCA Healthy Kids Day: Promoting Childhood Wellness

PhRMA  |  Blog Post

They are crucial to protecting our children so that they can have fun at events like the YMCA’s Healthy Kids Day.

How Does Insurance Cover Your Medicines?

Access Better Coverage  |  From Our Network

Watch our new video to help you learn more about health insurance, and check back for more tips on understanding your coverage.

New Medicines in Development for Women

PhRMA  |  Video

America’s pharmaceutical research and biotechnology companies continue making exciting progress in the search for new cures and treatments for diseases of special concern to women.

PhRMA Announces Promotions of Key Federal Affairs Staff

PhRMA  |  Press Release

PhRMA Internet Address: http://www.phrma.orgFor information on how innovative medicines save lives, visit: http://www.innovation.orgFor information on the Partnership for Prescription Assistance, visit: http://www.pparx.orgFor more information on public health emergencies, visit http://www.rxresponse.orgFor information on the danger of imported drugs, visit:

New prostate cancer treatment will get its first test in Omaha

From Hope To Cures  |  From Our Network

The society estimates that 220,800 new cases were found in 2015 and that 27,540 men died of the disease.

New Report: Clinical Trials and the Impact on State Economies

PhRMA  |  Blog Post

This analysis provides a new lens through which to view the economic and scientific footprint of the U.S. biopharmaceutical industry.

New report highlights need to speed patent examination

PhRMA  |  Blog Post

The United Kingdom’s Intellectual Property Office estimated that combined losses from each year of backlog in the U.S.

Rare Disease Day Should Last All Year

PhRMA  |  Blog Post

For example, America's biopharmaceutical research companies are today working on more than 400 new medicines to help treat a wide variety of rare diseases.

Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

PhRMA  |  Press Release

Scangos was appointed CEO of Biogen Idec in June 2010.

New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need

PhRMA  |  Blog Post

America’s biopharmaceutical companies are committed to bringing new medicines to patients in need, including those that are often most vulnerable – children – and we are proud to support this new initiative.

PhRMA Statement Regarding Prescription Drug User Fee Act Reauthorization

PhRMA  |  Press Release

PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Collaboration Is Key in Researching and Developing New Medicines

Chartpack  |  From Our Network

The Accelerating Medicines Partnership, Biomarkers Consortium and Lung Cancer Master Protocol are a few examples of current collaborative efforts.

Report Shows Buffalo Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases

PhRMA  |  Press Release

PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines.

New Policy Solutions for Innovative Treatment Delivery

PhRMA  |  Press Release

Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.

In biopharmaceutical research, if at first you don’t succeed, try again

PhRMA  |  Blog Post

See one biopharmaceutical researcher’s

John J. Castellani to Lead PhRMA as New President & CEO

PhRMA  |  Press Release

PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines.

#GOBOLDLY - New World TV

PhRMA  |  Video

Welcome to a new world where immunotherapy unleashes your body’s own immune system to fight cancer.

Health Care Communications

PhRMA  |  From PhRMA

Physician Survey on Pharmaceutical Company Activities and Information Read the results of a survey that emphasizes the value of biopharmaceutical company engagement with healthcare providers.

Negotiators Must Say “Aloha” to a 21st Century Trade Deal

PhRMA  |  Blog Post

Since, on average, it takes 10-15 years and more than $2 billion to bring a new medication to market, innovators will only be willing to undertake that investment if they have incentives to do so.

How to Get Payment Reforms Right

Access Better Coverage  |  From Our Network

Medicare currently follows this model, and it should remain a part of any new payments models.

New Chart Pack: Biopharmaceuticals in Government Programs

PhRMA  |  Blog Post

  Medicines in Medicare Part D Beneficiaries Save Through Plan Competition and Manufacturer Negotiations   Medicines in Medicare Part B Program Spending on Prescription Medicines Accounted for About 8% of Part B Spending in 2012   Medicines in Medicaid On Average, About 60% of the Initial Cost of Brand Medicines is Returned to States Through Rebates   Medicines in Veterans Affairs VA Formulary Covers Fewer Drugs Than Part D Medicines in 340B Without Significant Reforms 340B Will Continue to Grow as Uninsured Rate Declines Check out PhRMA’s other chart pack resources here and check back with our Medicare Monday series and 340B Spotlight as we take a deeper look at some of these charts in the coming weeks.

PhRMA Statement Regarding User Fee Act Reauthorization

PhRMA  |  Press Release

This enhanced review model targets completion of FDA assessments of efficacy and safety within the first review cycle and is intended to reduce the overall time until new medicines become available to patients, while maintaining FDA’s gold standard of safety and efficacy.

You have reviewed the first 150 results out of 1960. Each page contains 25 results. You're on page 6.

prev 1 2 3 4 5 6 next